Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Current Events' Category

Thursday Links

Part D drug spending grows 17%. Should alcoholics get liver transplants? Why isn’t personalized medicine here yet? Is the public option doomed? Whose lives should be saved?

Read the rest of this entry »

Weekend Links

Biosimilars: A guide. Is it time to end of the donut hole? The five biggest questions in (macro)economics. FDA and poop regulation. Value framework conference. NHS cancer patients missing out innovative drugs.

Read the rest of this entry »

VBID comes to Medicare Advantage

CMS announced last week that they are extending their value-based insurance design (VBID) program to more states and more patients.  I describe VBID and the proposed changes below. What is VBID? Value-Based Insurance Design (VBID) generally refers to health insurers’ efforts to structure enrollee cost sharing and other health plan design elements to encourage enrollees […]

Read the rest of this entry »

Friday Links

Google partners with GSK to form biotech firm. You are 6x more likely to be killed by the police in the US than in Canada. ICER myths? One area without racial disparities? 2 million Medicare beneficiaries are homebound.  How will they get the medical care they need?

Read the rest of this entry »

Clinton vs. Trump: A Healthcare Comparison

AJMC has a nice article summarizing some of the key differences between the two presidential candidates.  I paraphrase the article below. The future of the Affordable Care Act (ACA). Clinton wants to keep or even expand the ACA and wants to cap out-of-pocket drug costs.  Clinton has even called for a public option. On the […]

Read the rest of this entry »

Impact of Brexit on Pharma

There is a lot of talk that Brexit will be a disaster.  While I believe that much of this disaster talk is overblown, there are clear business implications.  Pharmafile provides an example of how Brexit would affect a small pharmaceutical company conducting clinical trials in the UK. In the latter case, UK-based pharmaceutical companies with no other […]

Read the rest of this entry »

Friday Links

Progress in the fight against pancreatic cancer? Pouring billions down the drain? Does calorie labeling work? When life gives you MACRA. A one size fits all formulary policy?

Read the rest of this entry »

Nothing NICE about ICER?

On it’s website, the Instititute for Clinical and Economic Review (ICER) claims that it is “…a trusted non-profit organization that evaluates evidence on the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. ” A recent article in Huffington Post however, disagrees.  They make two key […]

Read the rest of this entry »

Friday Links

‘Are you dead yet’? Digitizing you and me. The future of economics? After the election, will you be able to import drugs from Canada? Merger madness on hold?

Read the rest of this entry »

Friday Links

Monetizing your DNA. Government schools. Paging Dr. Google?  Not anytime soon. WHO to set drug prices? Is CAR-T a bust? Are not?

Read the rest of this entry »